Tranexamic acid for percutaneous nephrolithotomy.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
26 10 2023
26 10 2023
Historique:
pmc-release:
26
10
2024
medline:
27
10
2023
pubmed:
26
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
Percutaneous nephrolithotomy (PCNL) is the gold standard for the treatment of large kidney stones but comes with an increased risk of bleeding compared to other treatments, such as ureteroscopy and shock wave lithotripsy. Tranexamic acid (TXA) is an antifibrinolytic agent that has been used to reduce bleeding complications in other settings. To assess the effects of TXA in individuals with kidney stones undergoing PCNL. We performed a comprehensive literature search of the Cochrane Library, PubMed (including MEDLINE), Embase, Scopus, Global Index Medicus, trials registries, other sources of the grey literature, and conference proceedings. We applied no restrictions on the language of publication nor publication status. The latest search date was 11 May 2023. We included randomized controlled trials (RCTs) that compared treatment with PCNL with administration of TXA to placebo (or no TXA) for patients ≥ 18 years old. Two review authors independently classified studies and abstracted data. Primary outcomes were: blood transfusion, stone-free rate (SFR), and thromboembolic events (TEEs). Secondary outcomes were: adverse events (AEs), secondary interventions, major surgical complications, minor surgical complications, unplanned hospitalizations or readmissions, and hospital length of stay (LOS). We performed statistical analyzes using a random-effects model. We rated the certainty of evidence (CoE) according to the GRADE approach using a minimally contextualized approach with predefined thresholds for minimally clinically important differences (MCIDs). We analyzed 10 RCTs assessing the effect of systemic TXA in PCNL versus placebo (or no TXA) with 1883 randomized participants. Eight studies were published as full text. One was published in abstract proceedings, but it was separated into two separate studies for the purpose of our analyzes. Average stone surface area ranged 3.45 to 6.62 cm Based on 10 RCTs with substantial methodological limitations that lowered all CoE of effect, we found that systemic TXA in PCNL may reduce blood transfusions, major and minor surgical complications, and hospital LOS, as well as improve SFRs; however, it may increase AEs. We are uncertain about the effects of systemic TXA on other outcomes. Findings of this review should assist urologists and their patients in making informed decisions about the use of TXA in the setting of PCNL.
Sections du résumé
BACKGROUND
Percutaneous nephrolithotomy (PCNL) is the gold standard for the treatment of large kidney stones but comes with an increased risk of bleeding compared to other treatments, such as ureteroscopy and shock wave lithotripsy. Tranexamic acid (TXA) is an antifibrinolytic agent that has been used to reduce bleeding complications in other settings.
OBJECTIVES
To assess the effects of TXA in individuals with kidney stones undergoing PCNL.
SEARCH METHODS
We performed a comprehensive literature search of the Cochrane Library, PubMed (including MEDLINE), Embase, Scopus, Global Index Medicus, trials registries, other sources of the grey literature, and conference proceedings. We applied no restrictions on the language of publication nor publication status. The latest search date was 11 May 2023.
SELECTION CRITERIA
We included randomized controlled trials (RCTs) that compared treatment with PCNL with administration of TXA to placebo (or no TXA) for patients ≥ 18 years old.
DATA COLLECTION AND ANALYSIS
Two review authors independently classified studies and abstracted data. Primary outcomes were: blood transfusion, stone-free rate (SFR), and thromboembolic events (TEEs). Secondary outcomes were: adverse events (AEs), secondary interventions, major surgical complications, minor surgical complications, unplanned hospitalizations or readmissions, and hospital length of stay (LOS). We performed statistical analyzes using a random-effects model. We rated the certainty of evidence (CoE) according to the GRADE approach using a minimally contextualized approach with predefined thresholds for minimally clinically important differences (MCIDs).
MAIN RESULTS
We analyzed 10 RCTs assessing the effect of systemic TXA in PCNL versus placebo (or no TXA) with 1883 randomized participants. Eight studies were published as full text. One was published in abstract proceedings, but it was separated into two separate studies for the purpose of our analyzes. Average stone surface area ranged 3.45 to 6.62 cm
AUTHORS' CONCLUSIONS
Based on 10 RCTs with substantial methodological limitations that lowered all CoE of effect, we found that systemic TXA in PCNL may reduce blood transfusions, major and minor surgical complications, and hospital LOS, as well as improve SFRs; however, it may increase AEs. We are uncertain about the effects of systemic TXA on other outcomes. Findings of this review should assist urologists and their patients in making informed decisions about the use of TXA in the setting of PCNL.
Identifiants
pubmed: 37882229
doi: 10.1002/14651858.CD015122.pub2
pmc: PMC10600962
doi:
Substances chimiques
Tranexamic Acid
6T84R30KC1
Antifibrinolytic Agents
0
Hemostatics
0
Banques de données
ClinicalTrials.gov
['NCT04367155']
Types de publication
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD015122Informations de copyright
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
Int J Surg. 2016 Dec;36(Pt D):660-664
pubmed: 27856356
J Clin Epidemiol. 2013 Feb;66(2):158-72
pubmed: 22609141
BMC Urol. 2017 Jun 27;17(1):48
pubmed: 28655317
Lancet. 2020 Jun 20;395(10241):1927-1936
pubmed: 32563378
Cochrane Database Syst Rev. 2014 Nov 26;(11):CD010338
pubmed: 25426776
BMJ. 2011 Oct 19;343:d5701
pubmed: 22012809
Urol Ann. 2017 Jul-Sep;9(3):230-233
pubmed: 28794587
Cochrane Database Syst Rev. 2018 Dec 31;12:CD004328
pubmed: 30596479
Br J Urol. 1997 Dec;80(6):889-93
pubmed: 9439403
Urology. 2010 Mar;75(3):543-6, 546.e1
pubmed: 19854493
J Endourol. 2022 Jul;36(7):906-915
pubmed: 35072547
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Endourol. 2011 Jan;25(1):11-7
pubmed: 21247286
Cent European J Urol. 2022;75(1):81-89
pubmed: 35591967
Urol Clin North Am. 2006 Aug;33(3):353-64
pubmed: 16829270
Drugs. 2012 Mar 26;72(5):585-617
pubmed: 22397329
Blood Transfus. 2018 Jan;16(1):36-43
pubmed: 29337665
BJU Int. 2008 Mar;101(5):535-9
pubmed: 17922862
Cochrane Database Syst Rev. 2023 Jul 28;7:CD012607
pubmed: 37503906
Iran J Med Sci. 2019 Nov;44(6):457-464
pubmed: 31875080
Eur Urol Focus. 2022 Sep;8(5):1376-1385
pubmed: 34404619
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Urology. 2015 Apr;85(4):777-81
pubmed: 25704996
Transfusion. 2019 Feb;59(2):806-824
pubmed: 30516835
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005355
pubmed: 17253552
J Urol. 2013 May;189(5):1757-61
pubmed: 23123376
Urology. 2016 Jun;92:57-62
pubmed: 26968489
J Endourol. 2011 Feb;25(2):327-33
pubmed: 21214412
J Int Med Res. 2020 Apr;48(4):300060520917563
pubmed: 32345081
Ann R Coll Surg Engl. 2023 Feb;105(2):99-106
pubmed: 36720263
BJU Int. 2022 Jan;129(1):35-47
pubmed: 33630393
J Endourol. 2022 May;36(5):589-597
pubmed: 34861768
Shock. 2020 Mar;53(3):277-283
pubmed: 32044848
J Urol. 2014 Aug;192(2):316-24
pubmed: 24857648
Urol J. 2021 Jul 22;18(6):608-611
pubmed: 34291443
BMC Med Res Methodol. 2014 Dec 19;14:135
pubmed: 25524443
Crit Care. 2021 Nov 1;25(1):380
pubmed: 34724964
Urology. 2005 Jul;66(1):38-40
pubmed: 15992882
Thromb Res. 2015 Feb;135(2):231-42
pubmed: 25559460
Clin Med (Lond). 2012 Oct;12(5):467-71
pubmed: 23101150
Cochrane Database Syst Rev. 2023 Nov 13;11:CD013445
pubmed: 37955353
Cochrane Database Syst Rev. 2013 Aug 30;(8):CD001245
pubmed: 23990381
Curr Urol Rep. 2021 Dec 16;22(12):65
pubmed: 34913084
J Urol. 2007 Feb;177(2):576-9
pubmed: 17222636
Can Urol Assoc J. 2023 Jun;17(6):205-216
pubmed: 36952300
Cochrane Database Syst Rev. 2014 Feb 13;(2):CD003249
pubmed: 24523225
Eur Urol. 2016 Aug;70(2):382-96
pubmed: 26876328
Cochrane Database Syst Rev. 2018 Apr 15;4:CD000249
pubmed: 29656433
Cochrane Database Syst Rev. 2014 Nov 21;(11):CD006640
pubmed: 25414987
Minerva Urol Nefrol. 2019 Feb;71(1):55-62
pubmed: 30037208
Exp Ther Med. 2021 Mar;21(3):213
pubmed: 33574911
Transl Androl Urol. 2012 Dec;1(4):223-8
pubmed: 26816715
Cochrane Database Syst Rev. 2012;12:CD004896
pubmed: 23418644
Cochrane Database Syst Rev. 2015 Jun 16;(6):CD007872
pubmed: 26079202
Cochrane Database Syst Rev. 2013 Jul 23;(7):CD010562
pubmed: 23881695
Curr Opin Urol. 2003 May;13(3):235-41
pubmed: 12692448
Cochrane Database Syst Rev. 2016 Jan 23;(1):CD011732
pubmed: 26801659
Cochrane Database Syst Rev. 2016 Nov 02;11:CD008711
pubmed: 27806184
Eur Urol. 2012 Aug;62(2):246-55
pubmed: 22487016
Minerva Urol Nefrol. 2020 Oct;72(5):579-585
pubmed: 32573173
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD010245
pubmed: 23440847
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Eur Urol. 2012 Jul;62(1):160-5
pubmed: 22498635
Transl Androl Urol. 2014 Sep;3(3):278-83
pubmed: 26816777
Eur Urol. 2012 Jan;61(1):146-58
pubmed: 21978422
J Urol. 2013 Feb;189(2):568-73
pubmed: 23260552
BJU Int. 2006 Nov;98(5):1075-9
pubmed: 17034608
BMJ. 2014 Aug 12;349:g4829
pubmed: 25116268
Cochrane Database Syst Rev. 2016 Mar 15;3:CD009733
pubmed: 26978005
Anaesthesiol Intensive Ther. 2015;47(4):339-50
pubmed: 25797505
World J Urol. 2017 Aug;35(8):1233-1240
pubmed: 27995302
Cent European J Urol. 2011;64(3):156-8
pubmed: 24578884
Eur Urol. 2017 Aug;72(2):220-235
pubmed: 28237786
Urology. 2004 Nov;64(5):955-8
pubmed: 15533485
BJU Int. 2005 Mar;95 Suppl 2:78-84
pubmed: 15720340
Cochrane Database Syst Rev. 2013 Jul 29;(7):CD009733
pubmed: 23897323
JAMA Surg. 2021 Apr 14;:e210884
pubmed: 33851983
Cochrane Database Syst Rev. 2018 Feb 20;2:CD012964
pubmed: 29462500
Cochrane Database Syst Rev. 2015 May 09;(5):CD004896
pubmed: 25956410
World J Urol. 2015 Aug;33(8):1069-77
pubmed: 25218854
Cochrane Database Syst Rev. 2023 Oct 26;10:CD015122
pubmed: 37882229
BMJ. 2008 May 3;336(7651):995-8
pubmed: 18456631
Cochrane Database Syst Rev. 2016 Sep 19;9:CD006883
pubmed: 27643712
Korean J Urol. 2013 Jul;54(7):448-53
pubmed: 23878687
Cochrane Database Syst Rev. 2015 Dec 24;(12):CD011385
pubmed: 26704192
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583
J Endourol. 2022 Mar;36(3):303-312
pubmed: 34569280
BMJ. 2020 Jan 16;368:l6890
pubmed: 31948937
Urol Ann. 2019 Apr-Jun;11(2):180-186
pubmed: 31040605
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120